---
schema_version: "secwatch.filing_event.v1"
accession: "0001467373-25-000069"
form_type: "8-K"
ticker: "ACN"
cik: "0001467373"
company_name: "Accenture plc"
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:12:47.259156+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Accenture CEO Julie Sweet diagnosed with breast cancer; expects to continue leading company during treatment

## Summary
- Diagnosis caught early; prognosis 'excellent' and condition curable; PET scan shows no cancer elsewhere.
- Surgery next week; expected treatment includes radiation lasting 12 to 16 weeks.
- Sweet says she will work 'substantially as normal' leading day-to-day operations throughout treatment; will curtail travel.
- Board has been briefed and is fully supportive; Global Management Committee will support operations.

## SEC filing metadata
- accession: 0001467373-25-000069
- form_type: 8-K
- ticker: ACN
- cik: 0001467373
- company_name: Accenture plc
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1467373/000146737325000069/0001467373-25-000069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1467373/000146737325000069/acn-20250213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001467373-25-000069
- JSON: https://secwatch.observer/filing/0001467373-25-000069.json
- Plain text: https://secwatch.observer/filing/0001467373-25-000069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.